Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer

Twelves, C, Awada, A, Cortes, J et al. (6 more authors) (2016) Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer: Basic and Clinical Research, 10. pp. 77-84.

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2016, The Authors, Publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
Dates:
  • Published: 28 June 2016
  • Accepted: 8 April 2016
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 02 Dec 2016 16:27
Last Modified: 05 Oct 2017 16:26
Published Version: http://doi.org/10.4137/BCBCR.S39615
Status: Published
Publisher: Libertas Academica
Identification Number: https://doi.org/10.4137/BCBCR.S39615

Share / Export

Statistics